FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2735191652> ?p ?o ?g. }

• W2735191652 abstract "Idiopathic hypersomnia is a disorder of excessive daytime sleepiness, often accompanied by long sleep times or pronounced difficulty in awakening, in the absence of a known cause. The optimal treatment strategy for idiopathic hypersomnia is currently unknown.To assess the effects of medications for daytime sleepiness and related symptoms in individuals with idiopathic hypersomnia and, in particular, whether medications may: 1. reduce subjective measures of sleepiness; 2. reduce objective measures of sleepiness; 3. reduce symptoms of cognitive dysfunction; 4. improve quality of life; and 5. be associated with adverse events.We searched the following databases on 4 February 2021: Cochrane Register of Studies (CRS Web), MEDLINE (Ovid, 1946 to 1 February 2021), and reference lists of articles. CRS Web includes randomized or quasi-randomized controlled trials from PubMed, Embase, ClinicalTrials.gov, the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP), the Cochrane Central Register of Controlled Trials (CENTRAL), and the specialized registers of Cochrane Review Groups, including the Cochrane Epilepsy Group. We previously searched the WHO ICTRP separately when loading of ICTRP records into CRS Web was temporarily suspended.Randomized studies comparing any medication to placebo, another medication, or a behavioral intervention.Two review authors independently extracted data and assessed trial quality. We contacted study authors for additional data. We collected data on adverse events from the included trials.We included three trials, with a total of 112 participants. Risk of bias was low for the included studies. Two pharmaceutical company-sponsored trials compared modafinil with placebo, involving 102 participants, nearly all of whom had idiopathic hypersomnia without long sleep time. Modafinil significantly improved self-reported sleepiness on the Epworth Sleepiness Scale by 5.08 points more than placebo (95% confidence interval (CI) 3.01 to 7.16; 2 studies, 101 participants; high-certainty evidence). Modafinil also significantly improved disease severity on the Clinical Global Impression of Severity scale by 1.02 points (95% CI 0.11 to 1.93; 1 study, 30 participants; moderate-certainty evidence) and resulted in a greater proportion of participants who were much improved or very much improved on the Clinical Global Impression of Change (odds ratio (OR) for improvement 5.14, 95% CI 1.76 to 15.00; 1 study, 70 participants; moderate-certainty evidence). Ability to remain awake on the Maintenance of Wakefulness Test was significantly improved with modafinil, by 4.74 minutes more than with placebo (95% CI 2.46 to 7.01; 2 studies, 99 participants; high-certainty evidence). Ratings of exhaustion and effectiveness/performance were improved with modafinil compared to placebo in one study. Number of naps per week was no different between modafinil and placebo across two studies. Participants receiving modafinil experienced more side effects, although the difference did not reach statistical significance (OR 1.68, 95% CI 0.28 to 9.94; 2 studies, 102 participants; low-certainty evidence). One trial studying 20 participants with different disorders of sleepiness included 10 participants with idiopathic hypersomnia, with or without long sleep time, and compared clarithromycin to placebo. We only included the subset of trial data for those participants with idiopathic hypersomnia, per our protocol. There were no significant differences between clarithromycin and placebo for the Epworth Sleepiness Scale, psychomotor vigilance testing, sleep inertia, other subjective ratings, or side effects.Modafinil is effective for the treatment of several aspects of idiopathic hypersomnia symptomatology, based on studies predominantly including participants with idiopathic hypersomnia without long sleep times, with low risk of bias, and evidence certainty ranging from high to low. There is insufficient evidence to conclude whether clarithromycin is effective for the treatment of idiopathic hypersomnia. There is a clear need for additional studies testing interventions for the treatment of idiopathic hypersomnia." @default.
• W2735191652 created "2017-07-21" @default.
• W2735191652 creator A5004817747 @default.
• W2735191652 creator A5022239109 @default.
• W2735191652 creator A5066463668 @default.
• W2735191652 creator A5090228305 @default.
• W2735191652 date "2021-05-25" @default.
• W2735191652 modified "2023-09-23" @default.
• W2735191652 title "Medications for daytime sleepiness in individuals with idiopathic hypersomnia" @default.
• W2735191652 cites W1241659441 @default.
• W2735191652 cites W1560210197 @default.
• W2735191652 cites W1831307559 @default.
• W2735191652 cites W1968938258 @default.
• W2735191652 cites W1974088759 @default.
• W2735191652 cites W1976189538 @default.
• W2735191652 cites W1992425995 @default.
• W2735191652 cites W2015193889 @default.
• W2735191652 cites W2018690418 @default.
• W2735191652 cites W2021347905 @default.
• W2735191652 cites W2044635723 @default.
• W2735191652 cites W2059426332 @default.
• W2735191652 cites W2062996432 @default.
• W2735191652 cites W2064988355 @default.
• W2735191652 cites W2092721169 @default.
• W2735191652 cites W2097149283 @default.
• W2735191652 cites W2114211541 @default.
• W2735191652 cites W2131946783 @default.
• W2735191652 cites W2139532069 @default.
• W2735191652 cites W2142062933 @default.
• W2735191652 cites W2156962505 @default.
• W2735191652 cites W2167625943 @default.
• W2735191652 cites W2191710221 @default.
• W2735191652 cites W2333318701 @default.
• W2735191652 cites W2400995968 @default.
• W2735191652 cites W2405186425 @default.
• W2735191652 cites W2512371310 @default.
• W2735191652 cites W2735191652 @default.
• W2735191652 cites W2790797401 @default.
• W2735191652 cites W2978795816 @default.
• W2735191652 cites W3121383308 @default.
• W2735191652 cites W3159433241 @default.
• W2735191652 cites W4242576211 @default.
• W2735191652 cites W4297833403 @default.
• W2735191652 cites W54343044 @default.
• W2735191652 doi "https://doi.org/10.1002/14651858.cd012714.pub2" @default.
• W2735191652 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8144933" @default.
• W2735191652 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34031871" @default.
• W2735191652 hasPublicationYear "2021" @default.
• W2735191652 type Work @default.
• W2735191652 sameAs 2735191652 @default.
• W2735191652 citedByCount "3" @default.
• W2735191652 countsByYear W27351916522020 @default.
• W2735191652 countsByYear W27351916522021 @default.
• W2735191652 countsByYear W27351916522022 @default.
• W2735191652 crossrefType "journal-article" @default.
• W2735191652 hasAuthorship W2735191652A5004817747 @default.
• W2735191652 hasAuthorship W2735191652A5022239109 @default.
• W2735191652 hasAuthorship W2735191652A5066463668 @default.
• W2735191652 hasAuthorship W2735191652A5090228305 @default.
• W2735191652 hasBestOaLocation W27351916522 @default.
• W2735191652 hasConcept C118552586 @default.
• W2735191652 hasConcept C126322002 @default.
• W2735191652 hasConcept C142724271 @default.
• W2735191652 hasConcept C1513209611 @default.
• W2735191652 hasConcept C168563851 @default.
• W2735191652 hasConcept C169900460 @default.
• W2735191652 hasConcept C1862650 @default.
• W2735191652 hasConcept C187212893 @default.
• W2735191652 hasConcept C197934379 @default.
• W2735191652 hasConcept C204787440 @default.
• W2735191652 hasConcept C27081682 @default.
• W2735191652 hasConcept C2778205975 @default.
• W2735191652 hasConcept C2778664715 @default.
• W2735191652 hasConcept C2779034229 @default.
• W2735191652 hasConcept C2780714222 @default.
• W2735191652 hasConcept C2781326671 @default.
• W2735191652 hasConcept C2781433485 @default.
• W2735191652 hasConcept C535046627 @default.
• W2735191652 hasConcept C71924100 @default.
• W2735191652 hasConcept C95190672 @default.
• W2735191652 hasConceptScore W2735191652C118552586 @default.
• W2735191652 hasConceptScore W2735191652C126322002 @default.
• W2735191652 hasConceptScore W2735191652C142724271 @default.
• W2735191652 hasConceptScore W2735191652C1513209611 @default.
• W2735191652 hasConceptScore W2735191652C168563851 @default.
• W2735191652 hasConceptScore W2735191652C169900460 @default.
• W2735191652 hasConceptScore W2735191652C1862650 @default.
• W2735191652 hasConceptScore W2735191652C187212893 @default.
• W2735191652 hasConceptScore W2735191652C197934379 @default.
• W2735191652 hasConceptScore W2735191652C204787440 @default.
• W2735191652 hasConceptScore W2735191652C27081682 @default.
• W2735191652 hasConceptScore W2735191652C2778205975 @default.
• W2735191652 hasConceptScore W2735191652C2778664715 @default.
• W2735191652 hasConceptScore W2735191652C2779034229 @default.
• W2735191652 hasConceptScore W2735191652C2780714222 @default.
• W2735191652 hasConceptScore W2735191652C2781326671 @default.
• W2735191652 hasConceptScore W2735191652C2781433485 @default.
• W2735191652 hasConceptScore W2735191652C535046627 @default.
• W2735191652 hasConceptScore W2735191652C71924100 @default.
• W2735191652 hasConceptScore W2735191652C95190672 @default.

• next